Oric Pharmaceuticals CFO sells 13,400 shares

Oric Pharmaceuticals’ chief financial officer sold shares under a Rule 10b5-1 plan adopted May 26, 2026, after exercising options at $4.36 per share.

Rhea-AI Filing Summary

Oric Pharmaceuticals, Inc. Chief Financial Officer Dominic Piscitelli exercised options to acquire 13,400 common shares on September 28, 2026, at a $4.36 exercise price. He then sold 13,400 shares at a weighted average of $13.5267 per share; the reported sale-price range was $13.50 to $13.575. The sale was made under a Rule 10b5-1 trading plan adopted May 26, 2026. His reported option position after the exercise was 78,500 options.

Insider Trade Summary 10b5-1

Exercise and Sale: 13,400 shares ($123K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Piscitelli Dominic

Role Chief Financial Officer

Sold 13,400 shs ($181K)

Approx. gross sale proceeds $181K

Approx. exercise cost $58K

Approx. pre-tax spread $123K

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	13,400	$0.00	$0.00
Exercise	Common Stock	13,400	$4.36	$58K
Sale	Common Stock F1, F2	13,400	$13.5267	$181K

Holdings After Transaction: Stock Option (right to buy) — 78,500 contracts (Direct); Common Stock — 69,828 shares (Direct)

Footnotes (2)

1. F1. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 26, 2026.
2. F2. Represents the weighted average share price of an aggregate total of 13,400 shares sold in the price range of $13.50 to $13.575 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Key Figures

Shares acquired through option exercise: 13,400 shares Exercise price: $4.36 per share Shares sold: 13,400 shares +3 more

6 metrics

Shares acquired through option exercise 13,400 shares September 28, 2026

Exercise price $4.36 per share Options exercised on September 28, 2026

Shares sold 13,400 shares September 28, 2026

Weighted average sale price $13.5267 per share Sale on September 28, 2026

Reported sale-price range $13.50 to $13.575 per share For the 13,400 shares sold

Options after exercise 78,500 options Reported following the September 28, 2026 exercise

Key Terms

Rule 10b5-1 trading plan, weighted average share price, Stock Option (right to buy)

3 terms

Rule 10b5-1 trading plan regulatory

"pursuant to a Rule 10b5-1 trading plan adopted"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average share price financial

"weighted average share price of an aggregate total"

Stock Option (right to buy) financial

"Stock Option (right to buy)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ORIC shares did CFO Dominic Piscitelli sell?

Dominic Piscitelli, Oric Pharmaceuticals' chief financial officer, sold 13,400 shares on September 28, 2026, at a weighted average of $13.5267 per share. The reported sales ranged from $13.50 to $13.575 and were made under a Rule 10b5-1 trading plan adopted May 26, 2026.

What options did ORIC CFO Dominic Piscitelli exercise?

He exercised options to acquire 13,400 common shares on September 28, 2026, at a $4.36 exercise price. His reported option position after the exercise was 78,500 options.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/29/2026 - 07:16 PM Accepted by SEC EDGAR 09/29/2026 - 07:16 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Piscitelli Dominic

(Last) (First) (Middle)

C/O ORIC PHARMACEUTICALS, INC.

240 E. GRAND AVE., 2ND FLOOR

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Oric Pharmaceuticals, Inc. [ ORIC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/28/2026		M		13,400	A	$4.36	83,228	D
Common Stock	09/28/2026		S(1)		13,400	D	$13.5267(2)	69,828	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4.36	09/28/2026		M			13,400	07/20/2025	07/19/2032	Common Stock	13,400	$0	78,500	D

Explanation of Responses:

1. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 26, 2026.

2. Represents the weighted average share price of an aggregate total of 13,400 shares sold in the price range of $13.50 to $13.575 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

	/s/ Christian Kuhlen, attorney-in-fact	09/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)